 CAMBRIDGE, Mass., Aug. 05, 2021 GLOBE NEWSWIRE -- Intellia Therapeutics, Inc. NASDAQ:NTLA, a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPRCas9 technology both in vivo and ex vivo, today reported financial results for the second quarter ended June 30, 2021, and recent operational highlights. 